PDS Biotechnology Corporation Common Stock
Here’s whether PDS Biotechnology Corporation Common Stock (PDSB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-18.71% over 10 days); RSI 12 — oversold; weak 1-year return of -81.0%; 3-month momentum negative (-81.8%); rising volume on a downtrend (distribution, 2.76x avg). Currently 85.9% off its 52-week high. Score: -7/7.
PDSB is trading below its 200-day MA ($0.85) — a key warning sign the longer-term trend is under pressure. An RSI of 12.1 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -81.0% compares to +20.5% for SPY (trailed the market by 101.5%). The current 85.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.